Diseases associated with pheochromocytoma and retroperitoneal paraganglioma

Objective. To study the prevalence of comorbidities in pheochromocytoma/paraganglioma (PСHC/PG) in general and in different clinical forms in order to develop additional screening criteria for PСHC/PG. Materials and methods. The study included 336 patients with histologically verified PСHC/PG. Comorbidities were recorded retrospectively by analyzing the medical history from the initial examination in the medical records upon admission to the hospital for surgical treatment, both in the entire group and in subgroups of different clinical forms. Results. Overall, the following comorbidities were identified in the PСHC/PG group: grade 2 (16%) and grade 3 (63%) arterial hypertension, most commonly found in paroxysmal and mixed clinical forms; carbohydrate metabolism disorders, such as impaired glucose tolerance (>12.7%) and type 2 diabetes mellitus (21.7%), which are more characteristic of mixed and permanent clinical forms; ischemic heart disease (17.3%), which is most common in the mixed clinical form; extrasystole (12.2%); malignant neoplasms (9.2%), including endocrine cancers (8.3%); other endocrine diseases. Conclusion. The most common comorbidities in PСHC/PGhave been identified, which can be used as criteria for forming a risk group when screening for PСHC/PG. The characteristics of the clinical forms of PСHC/PG in relation to comorbidities have been identified.